Clay B. Siegall resigns from Nurix Therapeutics board effective May 15, 2022

Nurix Therapeutics, Inc.

Clay B. Siegall, Ph.D. resigned as Class II director and from Compensation Committee and Development Advisory Committee.
Resignation effective May 15, 2022; no reason provided in the filing.
No replacement named; board composition change disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Clay B. Siegall

Class II member of the Board

NRIX · Nurix Therapeutics, Inc.

Effective: 2022-05-15
Filed: May 16, 2022, 7:59 PM ET

On May 15, 2022, Clay B. Siegall, Ph.D., notified the board of directors (the “Board”) of Nurix Therapeutics, Inc. of his resignation as a Class II member of the Board and as a member of the Board’s Compensation Committee and Development Advisory Committee, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Clay B. Siegall resigned as Class II member of the Board at Nurix Therapeutics, Inc..

Action: resigned
Role: Class II member of the Board

Exact text from the filing

On May 15, 2022, Clay B. Siegall, Ph.D., notified the board of directors (the “Board”) of Nurix Therapeutics, Inc. of his resignation as a Class II member of the Board and as a member of the Board’s Compensation Committee and Development Advisory Committee, effective immediately.

View on SEC.gov

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-150768

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.